# Highlights of This Issue 593

## SPECIAL FEATURES

### CCR Translations

595  
New Treatments for Rhabdomyosarcoma: The Importance of Target Practice  
Frederic G. Barr  
*See article p. 796*

### Molecular Pathways

598  
Molecular Pathways: Targeting Mechanisms of Asbestos and Erionite Carcinogenesis in Mesothelioma  
Michele Carbone and Haining Yang

### CCR Focus

606  
A Millennium Goal for Cancer  
Susan E. Bates

607  
Overview of the AACR Clinical and Translational Cancer Research Think Tank Meeting  
Kenneth C. Anderson and Raymond N. DuBois

612  
Impact of Genomics on Personalized Cancer Medicine  
Carlos L. Arteaga and José Baselga

619  
Making Personalized Cancer Medicine a Reality: Challenges and Opportunities in the Development of Biomarkers and Companion Diagnostics  
David R. Parkinsson, Bruce E. Johnson, and George W. Sledge

625  
Genetically Modified Mouse Models for Biomarker Discovery and Preclinical Drug Testing  
Raju Kucherlapati

631  
Imaging: Strategies, Controversies, and Opportunities  
Ronald Blasberg and David Piwnica-Worms

638  
Reports from the 2010 Clinical and Translational Cancer Research Think Tank Meeting: Design Strategies for Personalized Therapy Trials  
Donald A. Berry, Roy S. Herbst, and Eric H. Rubin

### Review

645  
Cancer Dormancy: A Model of Early Dissemination and Late Cancer Recurrence  
David Páez, Melissa J. Labonte, Pierre Bohanes, Wu Zhang, Leonor Benhamin, Yan Ning, Takeru Wakatsuki, Fotios Loupakis, and Heinz-Josef Lenz

### HUMAN CANCER BIOLOGY

654  
Notch Signaling Promotes Growth and Invasion in Uveal Melanoma  

666  
Modeling a Lethal Prostate Cancer Variant with Small-Cell Carcinoma Features  
Vassiliki Tzelepi, Jieexin Zhang, Jing-Fang Lu, Brittany Kleb, Guanglin Wu, Xinhai Wan, Anh Hoang, Elena Efthathiou, Kanishka Sircar, Nora M. Navone, Patricia Troncoso, Shoudan Liang, Christopher J. Logothetis, Sankar N. Maiti, and Ana M. Aparicio

678  
Expansion of a CD8^+^PD-1^+^ Replicative Senescence Phenotype in Early Stage CLL Patients Is Associated with Inverted CD4:CD8 Ratios and Disease Progression  
Claudia Nunes, Ryan Wong, Malcolm Mason, Chris Fegan, Stephen Man, and Chris Pepper

688  
Primary Colorectal Cancers and Their Subsequent Hepatic Metastases Are Genetically Different: Implications for Selection of Patients for Targeted Treatment  

700  
Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas  
Seung-Mo Hong, Noriyuki Omura, Audrey Vincent, Ang Li, Spencer Knight, Jun Yu, Ralph H. Huban, and Michael Goggins
<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>713</td>
<td>Upregulated IL-19 in Breast Cancer Promotes Tumor Progression and Affects Clinical Outcome</td>
<td>Chung-Hsi Hsing, Hung-Chi Cheng, Yu-Hsiang Hsu, Chien-Hui Chan, Ching-Hua Yeh, Chien-Feng Li, and Ming-Shi Chang</td>
</tr>
<tr>
<td>726</td>
<td>Activation of β-Catenin Signaling in Androgen Receptor–Negative Prostate Cancer Cells</td>
<td>Xinhai Wan, Jie Liu, Jing-Fang Lu, Vassiliki Tzelepi, Jun Yang, Michael W. Starbuck, Lixia Diao, Jing Wang, Eleni Efthathiou, Elba S. Vazquez, Patricia Troncoso, Sankar N. Maity, and Nora M. Navone</td>
</tr>
<tr>
<td>737</td>
<td>MiR-1 Downregulation Cooperates with MACCI in Promoting MET Overexpression in Human Colon Cancer</td>
<td>Cristina Migliore, Valentina Martin, Vera P. Leoni, Angelo Restivo, Luigi Atzori, Annalisa Petrelli, Claudio Isella, Luigi Zorcolo, Ivana Sarotto, Giuseppe Casula, Paolo M. Comoglio, Amedeo Columbano, and Silvia Giordano</td>
</tr>
<tr>
<td>748</td>
<td>Oncogene Mutation Profiling of Pediatric Solid Tumors Reveals Significant Subsets of Embryonal Rhabdomyosarcoma and Neuroblastoma with Mutated Genes in Growth Signaling Pathways</td>
<td>Neerav Shukla, Nabahet Ameur, Ismail Yilmaz, Khaleda Nafa, Chyau-Yueh Lau, Angela Marchetti, Laetitia Borsu, Frederic G. Barr, and Marc Ladanyi</td>
</tr>
<tr>
<td>758</td>
<td>Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer</td>
<td>Jessica D. Sun, Qian Liu, Jingli Wang, Dharmendra Ahiwalia, Damien Ferraro, Yan Wang, Tian-Xin Duan, W. Steve Ammons, John G. Curd, Mark D. Matteucci, and Charles P. Hart</td>
</tr>
<tr>
<td>783</td>
<td>Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737</td>
<td>Keryn M. Lucas, Nethia Mohana-Kumaran, Diana Lau, Xu Dong Zhang, Peter Hersey, David C. Huang, Wolfgang Weninger, Nikolas K. Haass, and John D. Allen</td>
</tr>
<tr>
<td>796</td>
<td>Antitumor Activity of Sustained N-Myc Reduction in Rhabdomyosarcomas and Transcriptional Block by Antigene Therapy</td>
<td>Roberto Tonelli, Alan McIntyre, Consuelo Camerin, Zoe S. Walters, Korinne Di Leo, Joanna Selfe, Stefania Purgato, Edoardo Missiaiglia, Andrea Tortori, Jane Renshaw, Annalisa Astolfi, Kathryn R. Taylor, Salvatore Serravalle, Ryan Bishop, Cristina Nanni, Linda J. Valentijn, Andrea Faccini, Ivo Leuschner, Serena Formica, Jorge S. Reis-Filho, Valentina Ambrosini, Khin Thway, Monica Franzen, Brenda Summersgill, Rosangela Marchelli, Patrizia Hrelia, Giorgio Cantelli-Forti, Stefano Fant, Roberto Corradini, Andrea Pession, and Janet Shipley</td>
</tr>
</tbody>
</table>

**IMAGING, DIAGNOSIS, PROGNOSIS**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>808</td>
<td>Methylated RASSF1a Is the First Specific DNA Marker for Minimal Residual Disease Testing in Neuroblastoma</td>
<td>Janine Stutterheim, Fatima Ali Icl, Roxy den Ouden, Rogier Versteeg, Huib N. Caron, Godlike E.A.M. Tytgat, and C. Ellen van der Schoot</td>
</tr>
<tr>
<td>815</td>
<td>External Validation of Diagnostic Models to Estimate the Risk of Malignancy in Adnexal Masses</td>
<td>Caroline Van Holsbeke, Ben Van Calster, Tom Bourne, Silvia Ajossa, Antonio C. Testa, Stefano Guerriero, Robert Fruscio, Andrea Alberto Lissoni, Arturo Czekierdowski, Luca Savelli, Sabine Van Huffel, Lil Valentin, and Dirk Timmerman</td>
</tr>
<tr>
<td>826</td>
<td>Mitotic Checkpoints and Chromosome Instability Are Strong Predictors of Clinical Outcome in Gastrointestinal Stromal Tumors</td>
<td>Pauline Lagarde, Gaëlle Pérot, Audrey Kauffmann, Céline Bruard, Valérie Dapremont, Isabelle Hostein, Agnès Neuville, Agnieszka Wozniak, Raf Sciut, Patrick Schoffski, Alain Aurias, Jean-Michel Cointre, Maria Debiec-Rychter, and Frédéric Chibon</td>
</tr>
</tbody>
</table>

**CANCER THERAPY: PRECLINICAL**

<table>
<thead>
<tr>
<th>Page</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>758</td>
<td>Selective Tumor Hypoxia Targeting by Hypoxia-Activated Prodrug TH-302 Inhibits Tumor Growth in Preclinical Models of Cancer</td>
<td>Jessica D. Sun, Qian Liu, Jingli Wang, Dharmendra Ahiwalia, Damien Ferraro, Yan Wang, Tian-Xin Duan, W. Steve Ammons, John G. Curd, Mark D. Matteucci, and Charles P. Hart</td>
</tr>
</tbody>
</table>

**Clinical Cancer Research**

Downloaded from clincancerres.aacrjournals.org on December 30, 2017. © 2012 American Association for Cancer Research.
Pharmacokinetically Stabilized Cystine Knot Peptides That Bind Alpha-v-Beta-6 Integrin with Single-Digit Nanomolar Affinities for Detection of Pancreatic Cancer

Tumor Infiltration by T Lymphocytes Expressing Chemokine Receptor 7 (CCR7) Is Predictive of Favorable Outcome in Patients with Advanced Colorectal Carcinoma
Pierpaolo Correale, Maria Saveria Rotundo, Cirino Botta, Maria Teresa Del Vecchio, Chiara Ginanneschi, Antonella Licchetta, Raffaele Conca, Serena Apollinari, Fabio De Luca, Pierfrancesco Tassone, and Pierosandro Tagliaferri

CANCER THERAPY: CLINICAL

A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
Dung T. Le, Dirk G. Brockstedt, Ran Nir-Paz, Johannes Hampl, Shruti Mathur, John Nemunaitis, Daniel H. Sterman, Raffit Hassan, Eric Lutz, Bentley Moyer, Martin Giedlin, Jana-Lynn Louis, Elizabeth A. Sugar, Alice Pons, Andrea L. Cox, Jordana Levine, Aimee Luck Murphy, Peter Blei, Thomas W. Dubensky Jr, Joseph E. Eiden, Elizabeth M. Jaffee, and Daniel A. Laheru

Stem Cell Pathways Contribute to Clinical Chemoresistance in Ovarian Cancer
Adam D. Steg, Kerri S. Bevis, Ashwini A. Katre, Angela Ziebarth, Zachary C. Dobbins, Ronald D. Alvarez, Kui Zhang, Michael Conner, and Charles N. Landen

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Clinical Effects of Adjuvant Active Specific Immunotherapy Differ between Patients with Microsatellite-Stable and Microsatellite-Instable Colon Cancer
Vincent A. de Weger, Annelies W. Turksma, Quirinus J.M. Voorham, Zelda Euler, Herman Beil, Alfons J. van den Eertwegh, Elisabeth Bloemen, Herbert M. Pinedo, Jan B. Vermorken, Harm van Tinteren, Gerrit A. Meijer, and Erik Hooijberg

Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
Shuji Ogino, Kaori Shima, Jeffrey A. Meyerhardt, Nadine J. Mc Cleary, Kimmie Ng, Donna Hollis, Leonard B. Saltz, Robert J. Mayer, Paul Schaefer, Renaud Whit ton, Alexander Hantel, Al B. Benson III, Donna Spiegelman, Richard M. Goldberg, Monica M. Bertagno, and Charles S. Fuchs

Opposing Effects of Runx2 and Estradiol on Breast Cancer Cell Proliferation: In Vitro Identification of Reciprocally Regulated Gene Signature Related to Clinical Letrozole Responsiveness
Nym-Osor Chimge, Sanjeev K. Baniwal, Jingmin Luo, Simon Coetzee, Omar Khalid, Benjamin P. Berman, Debup Tripathy, Matthew J. Ellis, and Baruch Frenkel

LETTER TO THE EDITOR

Targeting Proteasomal Protein Degradation in Cancer—Letter
William K.K. Wu

CORRECTION

Correction: Improving T-cell Therapy for Relapsed EBV-Negative Hodgkin Lymphoma by Targeting Upregulated MAGE-A4

The Journal of Clinical and Translational Research v www.aacrjournals.org

Downloaded from clincancerres.aacrjournals.org on December 30, 2017. © 2012 American Association for Cancer Research.
ABOUT THE COVER

A section of endometrial tumor xenografted in a mouse injected with Wi38 fibroblasts that fail to support tumor vascularization. Immunofluorescence analysis with antibodies against CD31 (green) and Ki67 (red) shows lack of CD31-positive vasculature and Ki67-positive proliferating cells exclusively in the peripheral tumor layer (bottom), whereas injection of omental adipose stromal cells increases tumor proliferation and vascularization. For details, see the article by Klopp and colleagues on page 771 of this issue.